Primary & secondary progressive MS drug progress update
Primary & secondary progressive MS drug progress update
MedDay, a biotechnology company that develops new drugs for nervous system disorders, announced an update on the progress of its development pipeline with its lead product MD1003 for the treatment of primary and secondary progressive multiple sclerosis (MS). The first study is expected to be complete in early 2015, while the second should be complete in late 2015....... Read More - http://www.ms-uk.org/emergingtherapies
MS-UK - http://www.ms-uk.org/